(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.41%) $2 337.50
(0.98%) $27.52
(0.64%) $928.00
(-0.16%) $0.933
(-0.12%) $11.01
(-0.23%) $0.799
(0.00%) $92.17
4 days till quarter result
(bmo 2024-05-03)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF...
Stats | |
---|---|
今日成交量 | 92 932.00 |
平均成交量 | 206 541 |
市值 | 1.93B |
EPS | SEK0 ( 2024-02-28 ) |
下一个收益日期 | ( SEK0 ) 2024-05-03 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -5.37 |
ATR14 | SEK0.0510 (0.29%) |
音量 相关性
Vicore Pharma Holding AB 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Vicore Pharma Holding AB 相关性 - 货币/商品
Vicore Pharma Holding AB 财务报表
Annual | 2023 |
营收: | SEK0 |
毛利润: | SEK-3.42M (0.00 %) |
EPS: | SEK-3.22 |
FY | 2023 |
营收: | SEK0 |
毛利润: | SEK-3.42M (0.00 %) |
EPS: | SEK-3.22 |
FY | 2022 |
营收: | SEK0 |
毛利润: | SEK-3.61M (0.00 %) |
EPS: | SEK-3.99 |
FY | 2021 |
营收: | SEK0.00 |
毛利润: | SEK0.00 (0.00 %) |
EPS: | SEK-4.25 |
Financial Reports:
No articles found.
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。